<code id='4365203C45'></code><style id='4365203C45'></style>
    • <acronym id='4365203C45'></acronym>
      <center id='4365203C45'><center id='4365203C45'><tfoot id='4365203C45'></tfoot></center><abbr id='4365203C45'><dir id='4365203C45'><tfoot id='4365203C45'></tfoot><noframes id='4365203C45'>

    • <optgroup id='4365203C45'><strike id='4365203C45'><sup id='4365203C45'></sup></strike><code id='4365203C45'></code></optgroup>
        1. <b id='4365203C45'><label id='4365203C45'><select id='4365203C45'><dt id='4365203C45'><span id='4365203C45'></span></dt></select></label></b><u id='4365203C45'></u>
          <i id='4365203C45'><strike id='4365203C45'><tt id='4365203C45'><pre id='4365203C45'></pre></tt></strike></i>

          00:00
          00:00 00:00 LIVE
          buffering
          Replay
          LIVE
          00:00 / 00:00
          LIVE
          CC
          Opacity :
          Share:
          Close

          entertainment

          author:comprehensive    - browse:5726
          David L. Ryan/Boston Globe

          A team of high-powered scientists and billionaire investors said Friday that they’re launching a biomedical institute in Cambridge’s Kendall Square with $500 million in private funding with the aim of shortening the path from research breakthroughs to life-saving medicines.

          The institute, called Arena BioWorks, will put drug discovery and company creation under one roof, upending the traditional model where academic research and venture-backed drug development are separate.

          advertisement

          Backed by deep-pocketed investors including Steve Pagliuca, the former co-chair of Bain Capital and Celtics co-owner, and high-tech mogul Michael Dell, Arena has already lured top scientists from academic labs with lucrative compensation packages, but so far has publicly named only a few.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          Wikipedia